Source
10 developments in the corpus
Latest
Everything in the corpus, newest first.
SEP 8, 2026 · JOURNAL ARTICLE
JAMA Network Open
Large, rigorous meta-analysis of 38 randomized phase 3 trials with 31,721 patients showing statistically significant OS and disease-free survival benefits from ICIs in curative solid tumors, with no sex difference detected, though female underrepresentation limits generalizability.
SEP 8, 2026 · JOURNAL ARTICLE
JAMA Network Open
A cross-sectional survey of clinical practice and implementation challenges with no quantitative comparison group, efficacy data, or primary outcome measure; descriptive in nature and identifying barriers rather than testing an intervention or confirming an effect.
SEP 2, 2026 · JOURNAL ARTICLE
JAMA Network Open
A retrospective case series of 33 autopsy-confirmed CTE cases describing antemortem neuropsychological profiles; no control group, no prospective design, and limited sample size restrict evidence strength despite addressing an important diagnostic question.
Large, well-designed longitudinal cohort study with up to 18 years of follow-up, prespecified statistical correction, and consistent associations across cognitive and neuroimaging endpoints, though observational design and potential confounding limit practice-changing claims.
A well-designed prospective cohort study with 24-month follow-up and multivariate analysis identifies modifiable psychological mediators of post-treatment fatigue in breast cancer survivors, with clear effect sizes and controlled comparators.
AUG 12, 2026 · JOURNAL ARTICLE
JAMA Network Open
Large retrospective cohort study with over 1.15 million participants demonstrating consistent, adjusted associations between gestational diabetes and multiple postpartum cardiometabolic disorders with narrow confidence intervals, though observational design and commercial insurance population limit generalizability.
AUG 11, 2026 · JOURNAL ARTICLE
JAMA Network Open
A rigorous multicenter cross-sectional study applying a new clinical classification framework to a large, real-world MBS cohort, demonstrating differential risk profiles; results support the framework's potential but require prospective validation and longer-term outcome data.
AUG 11, 2026 · JOURNAL ARTICLE
JAMA Network Open
A randomized trial of reasonable design that failed its primary endpoint in intention-to-treat analysis but showed metabolic benefits in per-protocol subgroups; results suggest potential in adherent participants but require confirmation in larger, longer studies.